Specialty Spend Is on the Rise Again
EPIC recently unpacked everything you need to know about the state of specialty, with a specific focus on biosimilar and specialty generics.
We continue to see double-digit increases in per member per year cost for specialty drugs, and nearly 40% of that spend occurs in the medical benefit. Rigorous management across both benefits is critical to managing overall specialty spend. This webinar uncovered what is driving increased spend and what you can do about it.
Agenda:
- Deeper dive into specialty spend and what you can do about it
- Emerging trends in biosimilar medications
- Managing specialty generics
Meet Our Speakers:
Vice President Specialty Clinical Consultant
Pharmaceutical Strategies Group, an EPIC Company
Jeremy Sarich, PharmD, RPh, MBA
Sr. Consultant
Pharmaceutical Strategies Group, an EPIC Company
